NextCell Pharma: Blockbuster potential hidden in plain sight - Redeye

Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell therapy with disease-modifying potential in type 1 diabetes. Strong clinical data and upcoming phase II readouts in 2025–2026 could pave the way for an outlicensing deal, yet the valuation remains modest—offering a compelling opportunity.

Länk till analysen i sin helhet: https://www.redeye.se/research/1072849/blockbuster-potential-hidden-in-plain-sight?utm_source=finwire&utm_medium=RSS